创胜集团-B2024年中期报告

（以存續方式於開曼群島註冊的有限公司）股份代號 :6628 24592645464749505167 20244 30 20246 720248 28 •88135 Kumar Srinivasan 20246 720248 28 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman KY1-9008Cayman Islands 218B6-501215123 Kumar Srinivasan Kumar Srinivasan 3485 Skadden, Arps, Slate, Meagher & Flom1542 1617 86/10/11/16/17 110158 Walkers (Hong Kong)1815 6628 http://www.transcenta.com/ 8240 Walkers Corporate Limited190 Elgin Avenue, George TownGrand Cayman, KY1-9008Cayman Islands •20236 3036.120246 304.6CDMO•20236 3017.68.020246 309.620246 30•20236 309.38.320246 301.0•20236 30207.9104.920246 30103.0•20236 3058.026.620246 3031.4•20236 30245.3110.120246 30135.2 •20236 3036.120246 304.6CDMO•20236 3017.68.020246 309.620246 30•20236 30203.9108.420246 3095.5•20236 3048.722.620246 3026.1•20236 30232.0109.620246 30122.4 2024 Claudin18.2osemitamab (TST001)(G/GEJ)62024(ASCO)osemitamab (TST001)(G/GEJ)IIosemitamab (TST001)++CAPOXPD-L1Claudin18.2PFS12.6CDxClaudin18.2osemitamab(TST001)(FDA)(CDE)(MFDS)III(TranStar301)osemitamab(TST001)Claudin18.2(G/GEJ)(G/GEJ)Claudin18.2 blosozumab (TST002)42024WCO-IOF-ESCEO(SAD)1,200 mgblosozumab(TST002)85BMD3.52%6.20%BMD1.30%2.24%BMD(2.77%) GREMLIN-1TST003(FIH)42024(AACR)TST003-1001(TiP) HiCBosemitamab(TST001)GMP OsemitamabTST001ADCCClaudin18.2 •202442024AACRTranStar101PKosemitamab (TST001)TranStar102 •20246ASCOosemitamab (TST001)CAPOXTranStar102GClaudin18.2PFS12.6III Osemitamab (TST001)CDx •20244CDxClaudin18.2osemitamab (TST001)Claudin18.2TranStar301IIIosemitamab (TST001)III Blosozumab (TST002) •Blosozumab (TST002) SAD2024WCO-IOF-ESCEO42024(CSOBMR)1,200 mgblosozumab (TST002)85BMD3.52%6.20%BMD1.30%2.24%BMD(2.77%) TST003GREMLIN-1 •TST003-1001FIHTST003PK •2024AACRTST003-1001(TiP) TST013ADC •TST013ADCADCTOPO-IPKADCINDADCTST013 TST808B •TST808BTST808BTST808IgAIND •BMSTranStar102osemitamab (TST001)TranStar101•Claudin18.2CDxosemitamab (TST001)TranStar301III• •siRNAsiRNACDMO•ExcelPro CHOExcelPro CHOSZ 300171ExcelPro CHO CMCCDMO CMC •osemitamab (TST001)FDA Cosemitamab (TST001) •CDMO•2024 CDMO •siRNA osemitamab (TST001)Claudin18.2IIIFDA(MFDS)Claudin18.2 CMCHiCBCMCCDMO 14 PD-L1=1TGFβ=βMASP2=2IND=FIC=HPV=NSCLC=SLE=TMA=IgA=ACombo=Chemo=VEGFR2=2 (1) (2) 2024 osemitamab (TST001)MSB0254TST003 TST012 TST013 •Osemitamab (TST001)Claudin18.2III(TranStar301)osemitamab (TST001)Claudin18.2FDA(MFDS)Claudin18.2•MSB0254VEGFR2MSB0254IRP2D•TST003GREMLIN-1(FIH)•TST012ADCADC•TST013ADCADC MSB0254TST003osemitamab (TST001)osemitamab (TST001)Claudin18.2TST003MSB0254 OsemitamabTST001ADCCClaudin18.2 Osemitamab (TST001)Claudin18.2ADCCClaudin18.2(PDAC)(NSCLC)osemitamab (TST001)+/-Claudin18.2PDACNSCLC Claudin18.2Claudin18.2IIIClaudin18.238%Osemitamab (TST001)Claudin18.2ADCCADCCClaudin18.2osemitamab (TST001)55%osemitamab (TST001)Claudin18.2 2024EMAPMDA 2024osemitamab (TST001) •202442024AACRTranStar101PKosemitamab (TST001)TranStar102 •20246ASCOosemitamab (TST001)CAPOXTranStar102GClaudin18.2PFS12.6III OSEMITAMAB (TST001)CDX •20244Claudin18.2osemitamab (TST001)Claudin18.2TranStar301IIIosemitamab (TST001)III MSB0254VEGFR2 MSB0254VEGFR2MSB0254VEGFR-2VEGFR-2VEGFR-2IRP2D TST003GREMLIN-1 TST003GREMLIN-1 •TST003-1001FIHTST003PK•2024AACRTST003-1001(TiP) TST012ADC TST012ADCosemitamab (TST001)ADC TST013ADC TST013ADCADCADCTST013 •2024ADCIND blosozumab (TST002)TST004TST008TST801TST808 blosozumab (TST002)IITST801IgA(SLE)1844 Blosozumab (TST002) Blosozumab (TST002)blosozumabIIblosozumab(BMD)12blosozumabBMD17.7%BMD6.2%32blosozumab (TST002)85BMD1,200 mgblosozumab (TST002)85BMD3.52%6.20%BMD1.30%2.24%PK/PD •Blosozumab (TST002) SAD42024WCO-IOF-ESCEO2024(CSOBMR) TST004IgAMASP-2 TST0042 (MASP2)TST004IgAIgANMASP2I TST008MASP-2BAFF TST008MASP2B TST801 TST801BSLEIND TST808B TST808BTST808BTST808IgA •IND 18A.08(3) ADCC(ADC)SLEINDB osemitamab (TST001)BMSblosozumab (TST002)TST004ADC(Dana Farber Cancer Institute)(John HopkinsUniversity) Osemitamab (TST001) osemitamab (TST001)Claudin18.2PDACNSCLC 2022BMSosemitamab (TST001)BMS®PD-1Claudin18.2 osemitamab (TST001)Claudin18.2Claudin18.2osemitamab (TST001)Claudin18.2osemitamab (TST001)III(TranStar301) Claudin18.2CDxIII(TranStar301) Blosozumab (TST002) 2019LY-2541546 (Blosozumab)LY-3108653 LY-2950913 blosozumab (TST002)GMPINDIND blosozumab (TST002) TST004 2020GMPGLPGLP FDAINDTST004 TST003 TST801 SLEIgA osemitamab (TST001)TST003TST005ADCClaudin18.2 siRNAsiRNACDMO ••ExcelPro CHOExcelPro CHOSZ 300171ExcelPro CHO CMCCDMO CMC •osemitamab (TST001)FDA Cosemitamab (TST001) ADC •CDMO CDMO •CDMO•INDCMCsiRNAsiRNA osemitamab (TST001)(TranStar301)CMCCDMO2024 Osemitamab (TST001) •Claudin18.2osemitamab (TST001)(TranStar301)2024EMA•ESMO•Claudin18.2 TST003 •TST003I TST808 •TST808IND TST013 •TST013IND •osemitamab (TST001)IIIosemitamab (TST001)PDACNSCLCClaudin18.2•blosozumab (TST002)TST003 TST004TST012TST013TST008TST801TST808 CMC •CDMO CDMO •CDMO• 20246 3020236 30 1. 1. CDMOCDMO FFSCDMOFFSFFS 2.